The Quantitative Parameters Based on Marrow Metabolism Derived from Synthetic MRI: A Pilot Study of Prognostic Value in Participants with Newly Diagnosed Multiple Myeloma

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Mar 30

PMID 38553942

Authors

Sha Cui

Yinnan Guo

Weiran Niu

Jianting Li

Wenjin Bian

Wenqi Wu

Wenjia Zhang

Qian Zheng

Jun Wang

Jinliang Niu

Affiliations

Soon will be listed here.

Abstract

Background: The value of SyMRI-derived parameters from lumbar marrow for predicting early treatment response and optimizing the risk stratification of the Revised International Staging System (R-ISS) in participants with multiple myeloma (MM) is unknown.

Methods: We prospectively enrolled participants with newly diagnosed MM before treatment. The SyMRI of lumbar marrow was used to calculate T1, T2, and PD values and the clinical features were collected. All participants were divided into good response (≥VGPR) and poor response (<VGPR) groups after four treatment cycles. Univariate, multivariate analyses and ROC were used to identify prognostic significance. Mann-Whitney U-tests were used to compare the SyMRI parameters between genders. The value of optimizing the risk stratification was analyzed by Fisher's exact tests at each R-ISS stage.

Results: Fifty-nine participants (good response, n = 33; poor response, n = 26) were evaluated. The bone marrow plasma cell percentage, β-microglobulin, T1 and T2 value were difference between two groups (all p < 0.05). The T1 (odds ratio 1.003, p = 0.005) and T2 values (odds ratio 0.910, p = 0.002) were independent predictors and the AUC and cut-off values were 0.787, 967.2 ms and 0.784, 75.9 ms, respectively. There were no significant differences in SyMRI parameters between genders. Participants with both T1 value ≥967.2 ms and T2 value ≤75.9 ms in the R-ISS II stage were potentially to get poor response.

Conclusions: Synthetic MRI is a promising tool for predicting early treatment response to MM and promoting R-ISS II stage risk stratification.

Citing Articles

The quantitative parameters based on marrow metabolism derived from synthetic MRI: A pilot study of prognostic value in participants with newly diagnosed multiple myeloma.

Cui S, Guo Y, Niu W, Li J, Bian W, Wu W Cancer Med. 2024; 13(7):e7109.

PMID: 38553942 PMC: 10980927. DOI: 10.1002/cam4.7109.

References

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Shen Y, Mishima Y, Shi J, Sklavenitis-Pistofidis R, Redd R, Moschetta M . Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2020; 137(17):2360-2372. PMC: 8085483. DOI: 10.1182/blood.2020005885. View

Zhang W, Zhu J, Xu X, Fan G . Synthetic MRI of the lumbar spine at 3.0 T: feasibility and image quality comparison with conventional MRI. Acta Radiol. 2019; 61(4):461-470. DOI: 10.1177/0284185119871670. View

Hwang S, Panicek D . Magnetic resonance imaging of bone marrow in oncology, Part 1. Skeletal Radiol. 2007; 36(10):913-20. DOI: 10.1007/s00256-007-0309-3. View

Zhao L, Liang M, Xie L, Yang Y, Zhang H, Zhao X . Prediction of pathological prognostic factors of rectal cancer by relaxation maps from synthetic magnetic resonance imaging. Eur J Radiol. 2021; 138:109658. DOI: 10.1016/j.ejrad.2021.109658. View

Hillengass J, Landgren O . Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma". Leuk Lymphoma. 2013; 54(7):1355-63. DOI: 10.3109/10428194.2012.740559. View

Li J, Bai Y, Wu L, Zhang P, Wei X, Ma C . Synthetic relaxometry combined with MUSE DWI and 3D-pCASL improves detection of hippocampal sclerosis. Eur J Radiol. 2022; 157:110571. DOI: 10.1016/j.ejrad.2022.110571. View

Moulopoulos L, Dimopoulos M, Kastritis E, Christoulas D, Gkotzamanidou M, Roussou M . Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol. 2012; 87(9):861-4. DOI: 10.1002/ajh.23258. View

Hagiwara A, Warntjes M, Hori M, Andica C, Nakazawa M, Kumamaru K . SyMRI of the Brain: Rapid Quantification of Relaxation Rates and Proton Density, With Synthetic MRI, Automatic Brain Segmentation, and Myelin Measurement. Invest Radiol. 2017; 52(10):647-657. PMC: 5596834. DOI: 10.1097/RLI.0000000000000365. View

10.

Lacognata C, Crimi F, Guolo A, Varin C, De March E, Vio S . Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. Clin Radiol. 2017; 72(10):850-857. DOI: 10.1016/j.crad.2017.05.004. View

11.

BERGGARD I, Bearn A . Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids. J Biol Chem. 1968; 243(15):4095-103. View

12.

Sun M, Cheng J, Ren C, Zhang Y, Li Y, Li Y . Quantitative whole-body MR imaging for assessment of tumor burden in patients with multiple myeloma: correlation with prognostic biomarkers. Quant Imaging Med Surg. 2021; 11(8):3767-3780. PMC: 8245954. DOI: 10.21037/qims-20-1361. View

13.

Gracien R, Reitz S, Hof S, Fleischer V, Zimmermann H, Droby A . Changes and variability of proton density and T1 relaxation times in early multiple sclerosis: MRI markers of neuronal damage in the cerebral cortex. Eur Radiol. 2015; 26(8):2578-86. DOI: 10.1007/s00330-015-4072-x. View

14.

Yamauchi F, Penzkofer T, Fedorov A, Fennessy F, Chu R, Maier S . Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T(2)-mapping MRI sequence. Magn Reson Imaging. 2015; 33(5):525-30. PMC: 4426240. DOI: 10.1016/j.mri.2015.02.006. View

15.

DallOlio F, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N . Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 19(2):75-90. DOI: 10.1038/s41571-021-00564-3. View

16.

Koutoulidis V, Fontara S, Terpos E, Zagouri F, Matsaridis D, Christoulas D . Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. Radiology. 2016; 282(2):484-493. DOI: 10.1148/radiol.2016160363. View

17.

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

18.

Bataille R, Durie B, Grenier J . Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983; 55(3):439-47. DOI: 10.1111/j.1365-2141.1983.tb02158.x. View

19.

DAnastasi M, Notohamiprodjo M, Schmidt G, Durr H, Reiser M, Baur-Melnyk A . Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI. AJR Am J Roentgenol. 2014; 203(4):854-62. DOI: 10.2214/AJR.13.10724. View

20.

Cui Y, Han S, Liu M, Wu P, Zhang W, Zhang J . Diagnosis and Grading of Prostate Cancer by Relaxation Maps From Synthetic MRI. J Magn Reson Imaging. 2020; 52(2):552-564. DOI: 10.1002/jmri.27075. View